Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Taranchon-Clermont

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Revue Des Maladies Respiratoires|October 18, 2016
[Interest of crizotinib in a lung cancer patient with de novo amplification of MET]A Rabeau, I Rouquette, J-M Vantelon, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignanciesJ Remon, N Abedallaa, E Taranchon-Clermont, et al.
Oncogene|June 7, 2011
TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expressionC Ruptier, A De Gaspéris, S Ansieau, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Revue Des Maladies Respiratoires|October 18, 2016
[Interest of crizotinib in a lung cancer patient with de novo amplification of MET]A Rabeau, I Rouquette, J-M Vantelon, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignanciesJ Remon, N Abedallaa, E Taranchon-Clermont, et al.
Oncogene|June 7, 2011
TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expressionC Ruptier, A De Gaspéris, S Ansieau, et al.
Pageof 1